Natera, Inc. (NASDAQ:NTRA) is one of the best strong buy healthcare stocks to buy now. On June 30, RBC Capital analyst Conor McNamara maintained a Buy rating on Natera, Inc. (NASDAQ:NTRA) and set a price target of $251.00.
A laboratory environment with technicians in lab coats conducting molecular testing services.
Natera, Inc. reported a 36.5% increase in total revenue in fiscal Q1 2025 to $501.8 million, compared to $367.7 million in Q1 2024. Management attributed this growth to a 37.1% increase in product revenues, which reached $500.0 million in Q1 2025 compared to $364.7 million in the same quarter last year.
Growth in product revenues was primarily driven by a rise in volume and average selling price improvements, along with cash receipts collected during Q1 in excess of initial revenue estimates for tests delivered in previous quarters.
Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services, applying its technological services in oncology, women’s health, and organ health.
The company provides various diagnostic tests, including Panorama non-invasive prenatal test (NIPT), Vistara, Horizon carrier screening (HCS), Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis, Anora products of conception (POC), and non-invasive paternity testing (PAT).
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
